Diversity, inclusion and racial disparities
Karen Costenbader, MD, MPH
Brigham and Women's Hospital/ Harvard Medical School
BOSTON, MA, United States
Disclosure(s): Bristol-Myers Squibb(BMS): Consultant (Ongoing); Cabaletta: Consultant (Ongoing); Gilead: Grant/Research Support (Ongoing); Glaxo Smith Kline: Consultant (Ongoing); Janssen: Consultant (Ongoing), Grant/Research Support (Ongoing); Merck/MSD: Grant/Research Support (Ongoing)
This session will review how to improve clinical trial design and analysis for investigational therapies for rheumatic diseases. Speakers will address current challenges in patient accrual and strategies to overcome enrollment barriers, including broadening eligibility criteria and improving access to trials among underrepresented minorities. By highlighting the trial landscape in two rheumatic disease states (systemic sclerosis and systemic lupus erythematosus), the speakers will discuss the selection of meaningful and relevant endpoints, the use of external comparator control arms to minimize exposure to placebo, and ways to modernize trial design to discover new therapies (e.g., adaptive trial design).
Speaker: Saira Sheikh, MD – University of North Carolina at Chapel Hill
Speaker: Glen Hazlewood, MD, PhD, FRCPC – University of Calgary
Speaker: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School
Panelist: Janet Pope, MD;FRCPC;MPH – University of Western Ontario
Panelist: Saira Sheikh, MD – University of North Carolina at Chapel Hill
Panelist: Glen Hazlewood, MD, PhD, FRCPC – University of Calgary
Panelist: Karen Costenbader, MD, MPH – Brigham and Women's Hospital/ Harvard Medical School